Comparative Pharmacology
Head-to-head clinical analysis: APOKYN versus MIRAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APOKYN versus MIRAPEX.
APOKYN vs MIRAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apomorphine is a non-ergoline dopamine agonist that stimulates dopamine D2 and D1 receptors. It also activates D3, D4, and D5 receptors and has some serotonergic and adrenergic activity.
Dopamine receptor agonist (D3 > D2 > D4) with activity at α2-adrenergic and 5-HT1A receptors; increases dopamine receptor activation in striatum.
Subcutaneous injection: 0.2 mL (2 mg) as a test dose, then 0.1-0.6 mL (1-6 mg) as needed for episodes of hypomobility; maximum single dose: 0.6 mL (6 mg); maximum daily dose: 2.0 mL (20 mg).
Initial: 0.375 mg orally once daily; titrate gradually based on efficacy and tolerability. Usual effective dose: 1.5-4.5 mg daily in 3 divided doses. Maximum dose: 4.5 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 30–60 minutes (range 0.5–1 hour); clinically, rapid clearance necessitates continuous or frequent dosing for sustained effect
The terminal elimination half-life is 8–12 hours in healthy adults, allowing for three-times-daily dosing. In elderly patients, half-life may be prolonged to 12–14 hours due to age-related decline in renal function.
Renal (approx. 90% as metabolites and unchanged drug; <5% unchanged in urine); biliary/fecal (minor, <10%)
Renal elimination accounts for approximately 90% of total clearance, with about 80% recovered as unchanged parent drug in urine. Biliary/fecal excretion is minimal (<10%).
Category C
Category C
Dopamine Agonist
Dopamine Agonist